Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of IBIO-200 for COVID-19 infection

Trial Profile

A clinical study of IBIO-200 for COVID-19 infection

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2020

At a glance

  • Drugs IBIO 200 (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Apr 2020 New trial record

Trial Overview

Purpose

This trial will evaluate IBIO-200 for the treatment of COVID-19 infection.

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections treatment -

Subjects

  • Subject Type patients
  • Sex male & female

Trial Details

Organisations

  • Affiliations iBio Inc

Trial Dates

Other Details

  • Design prospective
  • Phase of Trial Phase I
  • Location Unknown
  • Focus Adverse reactions

Interventions

Drugs Route Formulation
IBIO 200Primary Drug
-
-

Trial History

Event Date Event Type Comment
03 Apr 2020 New trial record New trial record Updated 03 Apr 2020

References

  1. iBio Inc. iBio Announces Advancement of COVID-19 Vaccine Program. Media-Rel 2020;.

    Media Release
Back to top